USA and China plan increasing private-public collaboration in the health care sector

25 January 2011

On the occasion of the State Visit of China’s President Hu Jintao to the USA last week, the USA’s Trade and Development Agency (USTDA), Department of Health and Human Services (HHS) and Department of Commerce joined with China's Ministries of Health (MoH) and Commerce (MOFCOM) to announce their support for the establishment a new public-private partnership in the health care sector.

Initially, 12 US companies and six supporting organizations will participate in this partnership, alongside the supporting US and Chinese Government agencies. The partnership will be organized around US health care industry strengths and government capabilities in order to foster long-term cooperation with China in the areas of research, training, regulation and the adoption of an environment that will increase accessibility to health care services in China.

Initial participants include Abbott, J&J and Pfizer

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK